Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoidosis | 9 | 2024 | 535 | 4.280 |
Why?
|
Cardiomyopathies | 10 | 2024 | 2057 | 2.580 |
Why?
|
Peripheral Arterial Disease | 5 | 2024 | 1304 | 1.800 |
Why?
|
Myocarditis | 4 | 2023 | 802 | 1.620 |
Why?
|
Fractional Flow Reserve, Myocardial | 9 | 2024 | 346 | 1.450 |
Why?
|
Myocardial Perfusion Imaging | 11 | 2024 | 672 | 1.420 |
Why?
|
Fluorodeoxyglucose F18 | 8 | 2023 | 2055 | 1.350 |
Why?
|
Positron-Emission Tomography | 21 | 2024 | 6669 | 1.230 |
Why?
|
Eosinophilic Granuloma | 2 | 2017 | 27 | 1.160 |
Why?
|
Coronary Artery Disease | 20 | 2024 | 6568 | 1.150 |
Why?
|
Respiratory Sounds | 2 | 2017 | 702 | 0.840 |
Why?
|
Coronary Circulation | 12 | 2024 | 1617 | 0.710 |
Why?
|
Anthracyclines | 1 | 2022 | 286 | 0.690 |
Why?
|
Myocardial Infarction | 15 | 2024 | 11519 | 0.690 |
Why?
|
Exercise Therapy | 2 | 2024 | 939 | 0.680 |
Why?
|
Ventricular Function, Left | 7 | 2024 | 3941 | 0.630 |
Why?
|
Radiopharmaceuticals | 6 | 2023 | 2735 | 0.600 |
Why?
|
Nitrogen Oxides | 1 | 2017 | 128 | 0.580 |
Why?
|
Ultrasonography, Interventional | 2 | 2022 | 1524 | 0.560 |
Why?
|
Nitroglycerin | 1 | 2017 | 332 | 0.530 |
Why?
|
Lipoprotein(a) | 5 | 2024 | 489 | 0.530 |
Why?
|
Cardiovascular System | 1 | 2023 | 841 | 0.520 |
Why?
|
Angioplasty, Balloon | 1 | 2019 | 593 | 0.500 |
Why?
|
Heart Transplantation | 2 | 2019 | 3301 | 0.500 |
Why?
|
Exercise Test | 4 | 2021 | 2186 | 0.490 |
Why?
|
Burnout, Professional | 2 | 2020 | 711 | 0.480 |
Why?
|
Diabetic Angiopathies | 1 | 2019 | 806 | 0.460 |
Why?
|
Cardiology | 2 | 2023 | 1702 | 0.450 |
Why?
|
Registries | 14 | 2024 | 8375 | 0.430 |
Why?
|
Medicare | 4 | 2024 | 6809 | 0.420 |
Why?
|
Coronary Angiography | 8 | 2023 | 4541 | 0.400 |
Why?
|
Cardiovascular Agents | 1 | 2017 | 849 | 0.370 |
Why?
|
Cardiovascular Diseases | 7 | 2024 | 15662 | 0.360 |
Why?
|
Humans | 76 | 2024 | 768171 | 0.330 |
Why?
|
Ventricular Remodeling | 4 | 2022 | 1282 | 0.330 |
Why?
|
Thrombosis | 2 | 2022 | 2957 | 0.320 |
Why?
|
Heart Failure | 6 | 2023 | 11879 | 0.310 |
Why?
|
Lung | 2 | 2017 | 10101 | 0.310 |
Why?
|
Endovascular Procedures | 1 | 2022 | 2217 | 0.310 |
Why?
|
Glucose | 1 | 2019 | 4352 | 0.290 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3251 | 0.290 |
Why?
|
Stroke Volume | 6 | 2024 | 5622 | 0.280 |
Why?
|
Microcirculation | 4 | 2024 | 1281 | 0.260 |
Why?
|
Diabetes Mellitus | 3 | 2024 | 5891 | 0.260 |
Why?
|
Coronary Vessels | 6 | 2024 | 3124 | 0.260 |
Why?
|
Pre-Eclampsia | 2 | 2024 | 1255 | 0.240 |
Why?
|
Calcium | 3 | 2021 | 5792 | 0.220 |
Why?
|
Cough | 2 | 2017 | 598 | 0.210 |
Why?
|
Internship and Residency | 2 | 2020 | 5953 | 0.210 |
Why?
|
Plaque, Atherosclerotic | 1 | 2014 | 1551 | 0.210 |
Why?
|
Heart | 3 | 2021 | 4446 | 0.210 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20762 | 0.210 |
Why?
|
Predictive Value of Tests | 7 | 2024 | 15453 | 0.210 |
Why?
|
Insurance Benefits | 1 | 2024 | 185 | 0.210 |
Why?
|
Systemic Vasculitis | 1 | 2023 | 37 | 0.200 |
Why?
|
Prednisone | 2 | 2017 | 1567 | 0.200 |
Why?
|
Respiratory Function Tests | 2 | 2017 | 1695 | 0.200 |
Why?
|
Aged | 23 | 2024 | 171502 | 0.200 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2022 | 94 | 0.200 |
Why?
|
Retrospective Studies | 26 | 2024 | 81760 | 0.200 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 2 | 2024 | 1140 | 0.200 |
Why?
|
Atherosclerosis | 3 | 2024 | 3433 | 0.190 |
Why?
|
United States | 9 | 2024 | 73039 | 0.190 |
Why?
|
Radioisotopes | 1 | 2023 | 517 | 0.190 |
Why?
|
Female | 41 | 2024 | 397187 | 0.190 |
Why?
|
Cicatrix | 2 | 2024 | 798 | 0.190 |
Why?
|
Immunoglobulin E | 2 | 2017 | 1506 | 0.180 |
Why?
|
Vascular Resistance | 1 | 2024 | 939 | 0.180 |
Why?
|
Myocardial Ischemia | 2 | 2023 | 2138 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 560 | 0.180 |
Why?
|
Prognosis | 9 | 2024 | 30009 | 0.180 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2023 | 308 | 0.170 |
Why?
|
D-Amino-Acid Oxidase | 1 | 2019 | 26 | 0.170 |
Why?
|
Hypertension | 4 | 2024 | 8616 | 0.160 |
Why?
|
Intermittent Claudication | 1 | 2021 | 305 | 0.160 |
Why?
|
Middle Aged | 32 | 2024 | 223487 | 0.160 |
Why?
|
Treatment Outcome | 8 | 2024 | 65379 | 0.160 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2022 | 681 | 0.150 |
Why?
|
Thoracic Neoplasms | 1 | 2020 | 269 | 0.150 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 2032 | 0.150 |
Why?
|
Glucocorticoids | 2 | 2017 | 2167 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.140 |
Why?
|
Drug Administration Routes | 1 | 2017 | 152 | 0.140 |
Why?
|
Male | 35 | 2024 | 364731 | 0.140 |
Why?
|
Copper | 1 | 2019 | 368 | 0.140 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 428 | 0.130 |
Why?
|
Duodenum | 1 | 2019 | 495 | 0.130 |
Why?
|
Atrial Appendage | 1 | 2020 | 285 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1216 | 0.130 |
Why?
|
Hypolipidemic Agents | 1 | 2020 | 609 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3415 | 0.130 |
Why?
|
Renal Insufficiency, Chronic | 3 | 2024 | 2298 | 0.130 |
Why?
|
Constriction, Pathologic | 1 | 2019 | 1104 | 0.130 |
Why?
|
Prospective Studies | 6 | 2024 | 54924 | 0.130 |
Why?
|
Hydrogen Peroxide | 1 | 2019 | 741 | 0.130 |
Why?
|
Protease Inhibitors | 1 | 2019 | 751 | 0.130 |
Why?
|
Tachycardia, Ventricular | 1 | 2024 | 1309 | 0.120 |
Why?
|
Zinc | 1 | 2019 | 677 | 0.120 |
Why?
|
Fungal Proteins | 1 | 2019 | 906 | 0.120 |
Why?
|
Coronary Disease | 3 | 2019 | 5919 | 0.120 |
Why?
|
Risk Factors | 14 | 2024 | 74944 | 0.120 |
Why?
|
Cocaine-Related Disorders | 1 | 2018 | 458 | 0.120 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2018 | 340 | 0.120 |
Why?
|
Incidence | 6 | 2024 | 21538 | 0.120 |
Why?
|
Radiosurgery | 1 | 2024 | 1330 | 0.120 |
Why?
|
Recurrence | 2 | 2024 | 8509 | 0.110 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21207 | 0.110 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 13013 | 0.110 |
Why?
|
Walking | 1 | 2021 | 1201 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 629 | 0.110 |
Why?
|
Marijuana Abuse | 1 | 2018 | 409 | 0.110 |
Why?
|
Workload | 1 | 2019 | 849 | 0.110 |
Why?
|
Tetrazoles | 1 | 2019 | 923 | 0.110 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2019 | 843 | 0.110 |
Why?
|
Inflammation | 3 | 2023 | 10873 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1397 | 0.100 |
Why?
|
Neoplasms | 1 | 2021 | 22371 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1365 | 0.100 |
Why?
|
Boston | 3 | 2019 | 9374 | 0.100 |
Why?
|
Psoriasis | 1 | 2020 | 926 | 0.100 |
Why?
|
Academic Medical Centers | 2 | 2019 | 2785 | 0.100 |
Why?
|
Drug Combinations | 3 | 2023 | 2089 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 36741 | 0.100 |
Why?
|
Celiac Disease | 1 | 2019 | 820 | 0.090 |
Why?
|
Young Adult | 6 | 2022 | 60066 | 0.090 |
Why?
|
Echocardiography | 1 | 2024 | 5047 | 0.090 |
Why?
|
Treatment Failure | 1 | 2017 | 2661 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2024 | 2780 | 0.090 |
Why?
|
Myocardium | 2 | 2024 | 4790 | 0.090 |
Why?
|
Tomography, Optical Coherence | 1 | 2024 | 2957 | 0.090 |
Why?
|
Stents | 1 | 2022 | 3197 | 0.090 |
Why?
|
Myocytes, Cardiac | 1 | 2019 | 1682 | 0.090 |
Why?
|
Recovery of Function | 1 | 2020 | 2981 | 0.080 |
Why?
|
Risk Assessment | 7 | 2024 | 24318 | 0.080 |
Why?
|
Adult | 17 | 2024 | 223646 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2020 | 2145 | 0.080 |
Why?
|
Bone Marrow | 1 | 2019 | 2935 | 0.080 |
Why?
|
Time Factors | 5 | 2024 | 40220 | 0.080 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9540 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2171 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4262 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2020 | 2085 | 0.080 |
Why?
|
Age Factors | 3 | 2019 | 18415 | 0.080 |
Why?
|
Asthma | 2 | 2017 | 6291 | 0.080 |
Why?
|
Oxidative Stress | 1 | 2019 | 3140 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2420 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3626 | 0.070 |
Why?
|
Hospitals | 1 | 2019 | 3886 | 0.070 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59626 | 0.060 |
Why?
|
Follow-Up Studies | 7 | 2022 | 39354 | 0.060 |
Why?
|
Cohort Studies | 4 | 2022 | 41753 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3463 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3684 | 0.060 |
Why?
|
Mortality | 3 | 2021 | 2911 | 0.060 |
Why?
|
Aminopeptidases | 1 | 2024 | 114 | 0.060 |
Why?
|
Disease Management | 1 | 2014 | 2535 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14729 | 0.060 |
Why?
|
Heart Aneurysm | 1 | 2024 | 114 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2019 | 20225 | 0.050 |
Why?
|
Dideoxynucleosides | 1 | 2023 | 135 | 0.050 |
Why?
|
Age of Onset | 2 | 2021 | 3346 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 367 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2022 | 12543 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5520 | 0.050 |
Why?
|
Ammonia | 1 | 2022 | 247 | 0.050 |
Why?
|
Oxazines | 1 | 2023 | 358 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5176 | 0.050 |
Why?
|
Massachusetts | 3 | 2020 | 8890 | 0.050 |
Why?
|
Alanine | 1 | 2023 | 614 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2023 | 296 | 0.050 |
Why?
|
Drug Substitution | 1 | 2023 | 291 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3533 | 0.040 |
Why?
|
Anemia, Hypochromic | 1 | 2019 | 62 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2023 | 22290 | 0.040 |
Why?
|
Microvessels | 1 | 2024 | 585 | 0.040 |
Why?
|
Hospitalization | 1 | 2019 | 10840 | 0.040 |
Why?
|
Bone Marrow Examination | 1 | 2019 | 154 | 0.040 |
Why?
|
Mendelian Randomization Analysis | 1 | 2024 | 1040 | 0.040 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2023 | 701 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 819 | 0.040 |
Why?
|
Retinal Vessels | 1 | 2024 | 864 | 0.040 |
Why?
|
Mitochondria, Heart | 1 | 2019 | 236 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1339 | 0.040 |
Why?
|
Cause of Death | 2 | 2021 | 3721 | 0.040 |
Why?
|
Neovascularization, Physiologic | 1 | 2024 | 1370 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 795 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2019 | 1379 | 0.030 |
Why?
|
HIV Infections | 1 | 2023 | 17569 | 0.030 |
Why?
|
Postpartum Period | 1 | 2024 | 1197 | 0.030 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 711 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2022 | 5349 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2021 | 990 | 0.030 |
Why?
|
Nausea | 1 | 2019 | 682 | 0.030 |
Why?
|
Neprilysin | 1 | 2019 | 487 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2021 | 840 | 0.030 |
Why?
|
Survival Rate | 2 | 2020 | 12840 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2019 | 1890 | 0.030 |
Why?
|
Up-Regulation | 1 | 2024 | 4149 | 0.030 |
Why?
|
Troponin T | 1 | 2019 | 787 | 0.030 |
Why?
|
Dependovirus | 1 | 2019 | 720 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2019 | 1026 | 0.030 |
Why?
|
Reoperation | 1 | 2024 | 4329 | 0.030 |
Why?
|
Hemoglobins | 1 | 2019 | 1531 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2916 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2023 | 2258 | 0.030 |
Why?
|
Piperazines | 1 | 2023 | 2554 | 0.030 |
Why?
|
Heart Rate | 1 | 2024 | 4214 | 0.030 |
Why?
|
Pregnancy | 2 | 2024 | 30255 | 0.030 |
Why?
|
Propensity Score | 1 | 2020 | 1969 | 0.030 |
Why?
|
Fatigue | 1 | 2019 | 1557 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2021 | 2403 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15949 | 0.020 |
Why?
|
Administration, Oral | 1 | 2020 | 4034 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2024 | 3589 | 0.020 |
Why?
|
Dyspnea | 1 | 2019 | 1352 | 0.020 |
Why?
|
Obesity | 2 | 2024 | 13091 | 0.020 |
Why?
|
Chest Pain | 1 | 2018 | 1101 | 0.020 |
Why?
|
Contrast Media | 1 | 2024 | 5330 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26379 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3403 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6847 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2024 | 19025 | 0.020 |
Why?
|
Animals | 2 | 2019 | 169285 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6525 | 0.020 |
Why?
|
Insurance, Health | 1 | 2021 | 2517 | 0.020 |
Why?
|
Cerebral Hemorrhage | 1 | 2020 | 2654 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2019 | 2907 | 0.020 |
Why?
|
Risk | 1 | 2020 | 9613 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5797 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2566 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1885 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2023 | 4573 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7852 | 0.020 |
Why?
|
Prevalence | 1 | 2024 | 15869 | 0.020 |
Why?
|
Heart Diseases | 1 | 2020 | 2819 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10590 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3628 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10099 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3288 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4423 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4850 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9092 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9527 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6209 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2017 | 4887 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18349 | 0.010 |
Why?
|
Child, Preschool | 1 | 2022 | 42669 | 0.010 |
Why?
|
Stroke | 1 | 2020 | 9755 | 0.010 |
Why?
|